Lipum’s CEO on the merger with Flerie and the path toward phase II
20 november, 11:38
Lipum is approaching clinical phase II with SOL-116, the company’s antibody-based drug candidate targeting the enzyme BSSL – a central mediator of inflammatory processes in rheumatoid arthritis (RA). After presenting new research findings that further strengthen its scientific underpinnings, Lipum and Flerie have agreed on a merger plan which – if approved on 29 December – will see Lipum become a private portfolio company within the Flerie group. BioStock spoke with CEO Ola Sandborgh for a comment.
Read the full interview at biostock.se:
Lipum's CEO on the merger with Flerie and the path towards phase II
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
Ämnen i artikeln
Lipum’s CEO on the merger with Flerie and the path toward phase II
20 november, 11:38
Lipum is approaching clinical phase II with SOL-116, the company’s antibody-based drug candidate targeting the enzyme BSSL – a central mediator of inflammatory processes in rheumatoid arthritis (RA). After presenting new research findings that further strengthen its scientific underpinnings, Lipum and Flerie have agreed on a merger plan which – if approved on 29 December – will see Lipum become a private portfolio company within the Flerie group. BioStock spoke with CEO Ola Sandborgh for a comment.
Read the full interview at biostock.se:
Lipum's CEO on the merger with Flerie and the path towards phase II
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
Ämnen i artikeln
Fonder
Utredningen mot Intellego
Aktierekar
Försvarsaktier
Fonder
Utredningen mot Intellego
Aktierekar
Försvarsaktier
Marknadsöversikt
1 DAG %
Senast
1 mån
